Literature DB >> 30789234

Association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis-related calcinosis.

Kate Duffus1, Elena López-Isac2, Maria Teruel3, Carmen Pilar Simeón4, Patricia Carreria5, Norberto Ortego-Centeno6, Esther Vicente7, Jane Worthington1, Ariane L Herrick8,9, Javier Martin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30789234     DOI： 10.1093/rheumatology/kez015

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  3 in total

Review 1.  Calcinosis in systemic sclerosis.

Authors:  Srijana Davuluri; Christian Lood; Lorinda Chung
Journal:  Curr Opin Rheumatol       Date:  2022-08-19       Impact factor: 4.941

2.  Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium.

Authors:  Jose Manuel Sánchez-Maldonado; Ana Moñiz-Díez; Rob Ter Horst; Daniele Campa; Antonio José Cabrera-Serrano; Manuel Martínez-Bueno; María Del Pilar Garrido-Collado; Francisca Hernández-Mohedo; Laura Fernández-Puerta; Miguel Ángel López-Nevot; Cristina Cunha; Pedro Antonio González-Sierra; Jan Springer; Michaela Lackner; Laura Alcazar-Fuoli; Luana Fianchi; José María Aguado; Livio Pagano; Elisa López-Fernández; Esther Clavero; Leonardo Potenza; Mario Luppi; Lucia Moratalla; Carlos Solano; Antonio Sampedro; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; Federico Canzian; Juergen Loeffler; Yang Li; Hermann Einsele; Mihai G Netea; Lourdes Vázquez; Agostinho Carvalho; Manuel Jurado; Juan Sainz
Journal:  J Fungi (Basel)       Date:  2020-12-23

3.  Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma.

Authors:  Yongjie Zhou; Xin Zhou; Qingxin Liu; Zihan Zhang; Wen Zhang; Jingqin Ma; Minjie Yang; Jiaze Yu; Jianjun Luo; Zhiping Yan
Journal:  Dis Markers       Date:  2022-09-12       Impact factor: 3.464
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.